Free Trial

Eli Lilly and Company (LLY) Financials

Eli Lilly and Company logo
$776.26 -45.20 (-5.50%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$776.50 +0.24 (+0.03%)
As of 05/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Eli Lilly and Company

Annual Income Statements for Eli Lilly and Company

This table shows Eli Lilly and Company's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
2,408 2,738 -204 3,232 8,318 6,194 5,582 6,245 5,240 10,590
Consolidated Net Income / (Loss)
2,408 2,738 -204 3,232 8,318 6,194 5,582 6,245 5,240 10,590
Net Income / (Loss) Continuing Operations
2,408 2,738 -86 3,151 4,638 6,194 5,582 6,245 5,240 10,590
Total Pre-Tax Income
2,790 3,374 2,305 3,680 5,266 7,230 6,156 6,806 6,555 12,680
Total Operating Income
2,689 3,261 2,003 3,535 4,974 6,058 6,357 7,127 6,458 12,899
Total Gross Profit
14,922 15,512 15,526 16,812 17,598 19,057 21,006 21,912 27,042 36,624
Total Revenue
19,959 21,222 19,974 21,493 22,320 24,540 28,318 28,541 34,124 45,043
Operating Revenue
19,959 21,222 19,974 21,493 22,320 24,540 28,318 28,541 34,124 45,043
Total Cost of Revenue
5,037 5,710 4,448 4,682 4,721 5,483 7,313 6,630 7,082 8,418
Operating Cost of Revenue
5,037 5,710 4,448 4,682 4,721 5,483 7,313 6,630 7,082 8,418
Total Operating Expenses
12,232 12,251 13,523 13,277 12,624 12,999 14,649 14,784 20,584 23,725
Selling, General & Admin Expense
6,533 6,528 5,982 5,975 6,214 6,121 6,432 6,440 7,403 8,594
Research & Development Expense
5,331 5,340 6,209 7,035 5,835 6,746 7,901 8,099 13,113 14,271
Restructuring Charge
368 383 1,332 267 576 131 316 245 68 861
Total Other Income / (Expense), net
101 113 302 146 292 1,172 -202 -321 97 -219
Other Income / (Expense), net
101 113 302 146 292 1,172 -202 -321 97 -219
Income Tax Expense
382 636 2,391 530 628 1,036 574 562 1,314 2,090
Basic Earnings per Share
$2.27 $2.59 ($0.19) $3.14 $8.93 $6.82 $6.15 $6.93 $5.82 $11.76
Weighted Average Basic Shares Outstanding
1.06B 1.06B 1.05B 1.03B 931.06M 907.63M 906.96M 901.74M 900.18M 900.61M
Diluted Earnings per Share
$2.26 $2.58 ($0.19) $3.13 $8.89 $6.79 $6.12 $6.90 $5.80 $11.71
Weighted Average Diluted Shares Outstanding
1.07B 1.06B 1.05B 1.03B 935.68M 912.51M 911.68M 904.62M 903.28M 904.06M
Weighted Average Basic & Diluted Shares Outstanding
1.06B 1.06B 1.07B 1.03B 956.38M 958.43M 952.35M 950.30M 950.16M 948.17M
Cash Dividends to Common per Share
$2.00 $2.05 $2.12 $2.25 $2.58 $3.07 $3.53 $4.07 $4.69 $5.40

Quarterly Income Statements for Eli Lilly and Company

This table shows Eli Lilly and Company's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1,452 1,938 1,345 1,763 -57 2,190 2,243 2,967 970 4,410 2,759
Consolidated Net Income / (Loss)
1,452 1,938 1,345 1,763 -57 2,190 2,243 2,967 970 4,410 2,759
Net Income / (Loss) Continuing Operations
1,452 1,938 1,345 1,763 -57 2,190 2,243 2,967 970 4,410 2,759
Total Pre-Tax Income
1,566 2,096 1,530 2,089 427 2,509 2,536 3,517 1,588 5,039 3,456
Total Operating Income
1,677 1,836 1,494 2,126 450 2,388 2,509 3,715 1,526 5,149 3,695
Total Gross Profit
5,363 5,754 5,333 6,505 7,639 7,565 7,095 9,133 9,268 11,129 10,504
Total Revenue
6,942 7,302 6,960 8,312 9,499 9,353 8,768 11,303 11,439 13,533 12,729
Operating Revenue
6,942 7,302 6,960 8,312 9,499 9,353 8,768 11,303 11,439 13,533 12,729
Total Cost of Revenue
1,579 1,548 1,627 1,807 1,860 1,788 1,674 2,170 2,171 2,404 2,224
Operating Cost of Revenue
1,579 1,548 1,627 1,807 1,860 1,788 1,674 2,170 2,171 2,404 2,224
Total Operating Expenses
3,686 3,917 3,839 4,379 7,188 5,178 4,586 5,418 7,742 5,980 6,809
Selling, General & Admin Expense
1,614 1,643 1,749 1,925 1,804 1,925 1,952 2,117 2,100 2,425 2,469
Research & Development Expense
1,865 2,236 2,090 2,454 5,384 3,185 2,633 2,866 5,561 3,212 4,305
Restructuring Charge
207 - - 0.00 0.00 - - 435 82 - 35
Total Other Income / (Expense), net
-111 260 36 -37 -23 121 27 -198 62 -110 -239
Other Income / (Expense), net
-111 260 36 -37 -23 121 27 -198 62 -110 -239
Income Tax Expense
114 159 185 326 485 319 293 550 618 629 697
Basic Earnings per Share
$1.61 $2.15 $1.49 $1.96 ($0.06) $2.43 $2.49 $3.29 $1.08 $4.90 $3.07
Weighted Average Basic Shares Outstanding
900.70M 901.74M 901M 899.70M 899.80M 900.18M 900.80M 900.90M 901M 900.61M 898.70M
Diluted Earnings per Share
$1.61 $2.14 $1.49 $1.95 ($0.06) $2.42 $2.48 $3.28 $1.07 $4.88 $3.06
Weighted Average Diluted Shares Outstanding
903.80M 904.62M 903.30M 902.70M 899.80M 903.28M 903.80M 904.20M 905M 904.06M 900.60M
Weighted Average Basic & Diluted Shares Outstanding
950.18M 950.30M 949.27M 949.30M 949.31M 950.16M 950.41M 950.43M 949.32M 948.17M 947.74M

Annual Cash Flow Statements for Eli Lilly and Company

This table details how cash moves in and out of Eli Lilly and Company's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
-205 916 1,954 1,526 -5,661 1,320 161 -1,752 752 450
Net Cash From Operating Activities
2,965 4,851 5,616 5,525 4,837 6,500 7,366 7,586 4,240 8,818
Net Cash From Continuing Operating Activities
2,965 4,851 5,616 5,525 4,837 6,500 7,366 7,586 4,240 8,818
Net Income / (Loss) Continuing Operations
2,408 2,738 -204 3,232 8,318 6,194 5,582 6,245 5,240 10,590
Consolidated Net Income / (Loss)
2,408 2,738 -204 3,232 8,318 6,194 5,582 6,245 5,240 10,590
Depreciation Expense
1,428 1,497 1,567 1,609 1,233 1,324 1,548 1,523 1,527 1,767
Non-Cash Adjustments To Reconcile Net Income
753 285 1,394 2,236 -3,589 -470 1,324 1,543 2,573 3,752
Changes in Operating Assets and Liabilities, net
-1,624 332 2,859 -1,553 -1,126 -548 -1,088 -1,725 -5,101 -7,291
Net Cash From Investing Activities
27 -3,139 -3,784 1,906 -8,083 -2,259 -2,868 -3,763 -7,153 -9,302
Net Cash From Continuing Investing Activities
27 -3,139 -3,784 1,906 -8,083 -2,259 -2,868 -3,763 -7,153 -9,302
Purchase of Property, Plant & Equipment
-1,066 -1,037 -1,077 -1,211 -1,034 -1,388 -1,310 -1,854 -3,448 -5,058
Acquisitions
-5,843 -100 -1,969 -1,808 -7,611 -1,491 -1,416 -1,458 -4,989 -4,294
Purchase of Investments
-4,069 -5,673 -8,001 -950 -290 -370 -1,013 -708 -829 -776
Divestitures
- - 0.00 0.00 355 - 216 96 1,604 601
Sale and/or Maturity of Investments
5,230 3,728 7,439 6,062 746 887 847 464 700 523
Other Investing Activities, net
5,272 -130 -175 -188 -249 103 -192 -302 -192 -298
Net Cash From Financing Activities
-3,111 -560 143 -5,905 -2,325 -3,137 -4,131 -5,407 3,496 1,230
Net Cash From Continuing Financing Activities
-3,111 -560 143 -5,905 -2,325 -3,137 -4,131 -5,407 3,496 1,230
Repayment of Debt
-4,689 992 -995 -3,580 -2,071 -2,012 -2,201 -371 4,356 -3,007
Repurchase of Common Equity
-750 -600 -300 -4,151 -4,400 -500 -1,250 -1,500 -750 -2,500
Payment of Dividends
-2,127 -2,159 -2,192 -2,312 -2,410 -2,687 -3,087 -3,536 -4,069 -4,680
Issuance of Debt
4,455 1,207 3,630 2,478 6,556 2,062 2,407 0.00 3,959 11,417
Effect of Exchange Rate Changes
-86 -236 -21 - -90 216 - -168 169 -297

Quarterly Cash Flow Statements for Eli Lilly and Company

This table details how cash moves in and out of Eli Lilly and Company's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents
-5.50 -550 1,479 -851 -314 438 -358 763 145 -101 -175
Net Cash From Operating Activities
2,217 1,663 1,731 632 2,190 -312 1,166 1,466 3,712 2,474 1,666
Net Cash From Continuing Operating Activities
2,217 1,663 1,731 632 2,190 -312 1,166 1,466 3,712 2,474 1,666
Net Income / (Loss) Continuing Operations
1,452 1,938 1,345 1,763 -57 2,190 2,243 2,967 970 4,410 2,759
Consolidated Net Income / (Loss)
1,452 1,938 1,345 1,763 -57 2,190 2,243 2,967 970 4,410 2,759
Depreciation Expense
363 375 362 366 411 388 401 414 467 485 463
Non-Cash Adjustments To Reconcile Net Income
184 15 250 324 1,401 597 254 523 2,747 228 1,875
Changes in Operating Assets and Liabilities, net
218 -665 -227 -1,822 435 -3,486 -1,732 -2,439 -472 -2,649 -3,431
Net Cash From Investing Activities
-955 -944 -689 -459 -3,081 -2,924 -1,178 -2,199 -4,005 -1,921 -3,352
Net Cash From Continuing Investing Activities
-955 -944 -689 -459 -3,081 -2,924 -1,178 -2,199 -4,005 -1,921 -3,352
Purchase of Property, Plant & Equipment
-617 -501 -669 -738 -970 -1,071 -986 -1,225 -1,351 -1,496 -1,510
Acquisitions
-35 -465 -235 -98 -3,031 -1,625 -97 -1,126 -2,820 -251 -1,757
Purchase of Investments
-255 -169 -169 -234 -151 -275 -142 -157 -295 -182 -197
Sale and/or Maturity of Investments
109 129 343 155 133 69 112 214 100 97 72
Other Investing Activities, net
-223 32 40 457 -666 -23 -65 96 -170 -159 39
Net Cash From Financing Activities
-1,263 -1,141 412 -1,033 572 3,545 -311 1,556 211 -225 1,380
Net Cash From Continuing Financing Activities
-1,263 -1,141 412 -1,033 572 3,545 -311 1,556 211 -225 1,380
Repayment of Debt
-381 -257 -1,779 -16 1,588 4,563 -5,595 2,728 -3,137 2,997 -2,535
Repurchase of Common Equity
- - -750 - - - 0.00 - -446 -2,054 -1,200
Payment of Dividends
-882 -884 -1,017 -1,018 -1,016 -1,018 -1,169 -1,172 -1,171 -1,168 -1,346
Issuance of Debt
- - 3,959 - - - 6,453 - 4,965 - 6,461
Effect of Exchange Rate Changes
-3.60 -128 25 9.20 5.30 129 -36 -60 227 -429 132

Annual Balance Sheets for Eli Lilly and Company

This table presents Eli Lilly and Company's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets
35,569 38,806 44,981 43,908 39,286 46,633 48,806 49,490 64,006 78,715
Total Current Assets
12,574 15,101 19,202 20,550 13,710 17,462 18,452 18,035 25,727 32,740
Cash & Equivalents
3,666 4,582 6,536 7,321 2,338 3,657 3,819 2,067 2,819 3,268
Short-Term Investments
785 1,457 1,498 88 101 24 90 145 109 155
Accounts Receivable
4,072 4,766 5,262 5,777 5,542 6,929 8,127 8,559 11,336 13,275
Inventories, net
3,446 3,562 4,458 3,098 3,191 3,980 3,886 4,310 5,773 7,589
Prepaid Expenses
604 735 1,448 2,037 2,539 2,872 2,531 2,947 5,541 8,341
Other Current Assets
- - - - - - - 7.30 150 111
Plant, Property, & Equipment, net
8,054 8,253 8,827 7,996 7,873 8,682 8,985 10,144 12,914 17,102
Total Noncurrent Assets
14,942 15,452 16,952 15,363 17,704 20,489 21,369 21,311 25,366 28,873
Long-Term Investments
3,647 5,208 5,679 2,005 1,962 2,967 3,213 2,902 3,052 3,216
Goodwill
4,040 3,973 4,370 1,367 3,679 3,767 3,892 4,073 4,940 5,770
Intangible Assets
5,035 4,358 4,029 1,068 6,618 7,450 7,692 7,207 6,907 6,166
Noncurrent Deferred & Refundable Income Taxes
- - 1,166 2,614 2,573 2,830 2,489 2,793 5,477 8,001
Other Noncurrent Operating Assets
2,221 1,914 1,708 1,825 2,871 3,475 4,083 4,337 4,990 5,720
Total Liabilities & Shareholders' Equity
35,569 38,806 44,981 43,908 39,286 46,633 48,806 49,490 64,006 78,715
Total Liabilities
20,979 24,725 33,313 32,999 36,587 40,808 39,651 38,714 53,143 64,443
Total Current Liabilities
8,230 10,987 14,536 11,888 11,775 12,482 15,053 17,138 27,293 28,377
Short-Term Debt
6.10 1,937 3,707 1,102 1,499 8.70 1,538 1,501 6,905 5,117
Accounts Payable
1,338 1,349 1,411 1,207 1,405 1,607 1,671 1,931 2,599 3,229
Dividends Payable
539 548 591 651 672 771 886 1,017 1,169 1,346
Current Employee Benefit Liabilities
967 897 998 956 916 997 958 1,060 1,650 2,094
Other Current Liabilities
5,020 6,136 7,297 6,886 7,123 8,603 9,873 11,630 14,970 16,591
Total Noncurrent Liabilities
12,749 13,739 18,777 21,111 24,812 28,326 24,599 21,576 25,849 36,067
Long-Term Debt
7,972 8,368 9,941 9,196 13,818 16,587 15,346 14,738 18,321 28,527
Noncurrent Deferred Revenue
869 689 3,777 3,700 3,607 3,838 3,920 3,710 3,849 4,061
Noncurrent Employee Benefit Liabilities
2,160 2,454 3,514 2,802 3,698 4,095 1,954 1,305 1,439 1,301
Other Noncurrent Operating Liabilities
1,747 2,228 1,546 1,358 1,501 1,708 1,644 1,824 2,241 2,178
Commitments & Contingencies
- - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
14,590 14,081 11,668 10,909 2,699 5,825 9,155 10,775 10,864 14,272
Total Preferred & Common Equity
14,571 14,008 11,592 9,829 2,607 5,642 8,979 10,650 10,772 14,192
Total Common Equity
14,571 14,008 11,592 9,832 2,607 5,642 8,979 10,650 10,772 14,192
Common Stock
6,243 6,329 6,506 7,245 7,284 7,377 7,430 7,516 7,844 8,032
Retained Earnings
16,012 16,046 13,894 11,396 4,920 7,830 8,959 10,043 10,312 13,545
Treasury Stock
-90 -81 -76 -69 -61 -56 -53 -51 -44 -50
Accumulated Other Comprehensive Income / (Loss)
-4,581 -5,274 -5,719 -5,729 -6,524 -6,496 -4,343 -3,845 -4,327 -4,322
Other Equity Adjustments
-3,013 -3,013 -3,013 -3,010 -3,013 -3,013 -3,013 -3,013 -3,013 -3,013
Noncontrolling Interest
19 73 76 1,080 92 184 176 126 92 80

Quarterly Balance Sheets for Eli Lilly and Company

This table presents Eli Lilly and Company's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Total Assets
47,462 49,490 53,163 54,814 57,916 64,006 63,944 71,875 75,607 78,715 89,389
Total Current Assets
17,640 18,035 20,811 21,332 23,007 25,727 25,189 30,204 31,415 32,740 41,261
Cash & Equivalents
2,617 2,067 3,546 2,695 2,381 2,819 2,460 3,224 3,369 3,268 3,093
Short-Term Investments
125 145 123 135 113 109 126 140 149 155 127
Accounts Receivable
8,325 8,559 9,022 9,171 10,364 11,336 10,014 13,079 12,052 13,275 14,003
Inventories, net
3,831 4,310 4,545 4,799 4,901 5,773 6,102 6,482 7,460 7,589 9,311
Prepaid Expenses
2,742 2,947 3,575 4,532 5,248 5,541 6,349 7,138 8,251 8,341 14,654
Other Current Assets
- 7.30 - - - 150 139 142 135 111 72
Plant, Property, & Equipment, net
9,311 10,144 10,546 11,277 11,863 12,914 13,624 14,829 16,172 17,102 18,474
Total Noncurrent Assets
20,510 21,311 21,805 22,205 23,045 25,366 25,131 26,841 28,020 28,873 29,654
Long-Term Investments
2,575 2,902 2,750 2,745 2,692 3,052 3,087 2,878 3,200 3,216 3,223
Goodwill
3,892 4,073 4,073 4,079 4,085 4,940 4,940 5,768 5,768 5,770 5,771
Intangible Assets
7,124 7,207 7,087 6,904 6,782 6,907 6,762 6,636 6,537 6,166 6,012
Noncurrent Deferred & Refundable Income Taxes
2,384 2,793 3,407 3,806 4,575 5,477 5,634 6,655 7,392 8,001 8,573
Other Noncurrent Operating Assets
4,536 4,337 4,488 4,672 4,912 4,990 4,708 4,904 5,122 5,720 6,075
Total Liabilities & Shareholders' Equity
47,462 49,490 53,163 54,814 57,916 64,006 63,944 71,875 75,607 78,715 89,389
Total Liabilities
37,296 38,714 41,868 43,665 46,608 53,143 51,046 58,239 61,286 64,443 73,542
Total Current Liabilities
15,653 17,138 16,010 18,915 21,998 27,293 18,598 27,121 24,674 28,377 30,068
Short-Term Debt
1,745 1,501 3.10 662 2,245 6,905 1,652 5,162 2,074 5,117 4,016
Accounts Payable
1,683 1,931 2,016 2,474 2,435 2,599 2,474 2,925 2,887 3,229 3,442
Dividends Payable
0.00 1,017 0.00 1,016 0.00 1,169 0.00 1,171 0.00 1,346 0.00
Current Deferred & Payable Income Tax Liabilities
686 - 1,528 1,234 1,978 - - - - - 6,176
Current Employee Benefit Liabilities
984 1,060 740 868 1,233 1,650 844 1,168 1,703 2,094 1,114
Other Current Liabilities
10,555 11,630 11,723 12,662 14,108 14,970 13,629 16,696 18,010 16,591 15,320
Total Noncurrent Liabilities
21,643 21,576 25,858 24,750 24,610 25,849 32,448 31,118 36,612 36,067 43,474
Long-Term Debt
14,144 14,738 18,881 18,158 17,924 18,321 24,560 23,730 29,045 28,527 34,500
Noncurrent Deferred Revenue
3,642 3,710 3,842 3,331 3,468 3,849 4,189 3,497 3,879 4,061 5,371
Noncurrent Employee Benefit Liabilities
1,833 1,305 1,313 1,309 1,312 1,439 1,428 1,420 1,449 1,301 1,316
Other Noncurrent Operating Liabilities
1,853 1,824 1,823 1,952 1,906 2,241 2,271 2,471 2,239 2,178 2,288
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
10,166 10,775 11,295 11,149 11,307 10,864 12,897 13,636 14,321 14,272 15,847
Total Preferred & Common Equity
10,070 10,650 11,190 11,064 11,220 10,772 12,812 13,562 14,240 14,192 15,765
Total Common Equity
10,070 10,650 11,190 11,064 11,220 10,772 12,812 13,562 14,240 14,192 15,765
Common Stock
7,423 7,516 7,387 7,542 7,754 7,844 7,604 7,808 7,934 8,032 7,503
Retained Earnings
10,007 10,043 10,639 10,369 10,310 10,312 12,554 13,178 13,627 13,545 15,100
Treasury Stock
-51 -51 -45 -45 -45 -44 -33 -33 -33 -50 -50
Accumulated Other Comprehensive Income / (Loss)
-4,296 -3,845 -3,777 -3,789 -3,785 -4,327 -4,300 -4,379 -4,275 -4,322 -3,775
Other Equity Adjustments
-3,013 -3,013 -3,013 -3,013 -3,013 -3,013 -3,013 -3,013 -3,013 -3,013 -3,013
Noncontrolling Interest
96 126 105 86 87 92 85 74 81 80 82

Annual Metrics and Ratios for Eli Lilly and Company

This table displays calculated financial ratios and metrics derived from Eli Lilly and Company's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
1.75% 6.33% -5.88% 7.61% 3.84% 9.95% 15.40% 0.79% 19.56% 32.00%
EBITDA Growth
-3.69% 15.48% -20.50% 36.60% 22.87% 31.63% -9.95% 8.12% -2.97% 78.76%
EBIT Growth
-7.01% 20.93% -31.69% 59.67% 43.09% 37.30% -14.86% 10.57% -3.70% 93.46%
NOPAT Growth
9.55% 13.98% -102.84% 4,129.35% 44.78% 18.46% 11.07% 13.44% -21.04% 108.65%
Net Income Growth
0.75% 13.67% -107.46% 1,683.54% 157.38% -25.54% -9.88% 11.88% -16.08% 102.08%
EPS Growth
1.35% 14.16% -107.36% 1,747.37% 184.03% -23.62% -9.87% 12.75% -15.94% 101.90%
Operating Cash Flow Growth
-33.51% 63.63% 15.76% -1.62% -12.45% 34.38% 13.33% 2.98% -44.10% 107.96%
Free Cash Flow Firm Growth
-206.41% 211.79% -64.21% 467.12% -134.02% 207.08% -14.66% 36.81% -193.35% 82.11%
Invested Capital Growth
64.25% -8.81% -10.92% -41.23% 99.37% 15.79% 19.71% 15.72% 36.48% 36.27%
Revenue Q/Q Growth
1.29% 1.85% -11.11% 12.42% 2.18% 5.71% 2.02% -2.39% 6.40% 10.23%
EBITDA Q/Q Growth
-1.52% 10.14% -10.06% 9.73% 12.68% 10.79% -6.68% 2.28% 5.55% 22.23%
EBIT Q/Q Growth
-2.41% 15.29% -17.84% 17.03% 16.25% 12.55% -9.27% 3.92% 6.71% 24.92%
NOPAT Q/Q Growth
5.56% 6.23% -103.94% 564.66% 4.24% 9.45% 1.81% -1.51% 7.63% 28.86%
Net Income Q/Q Growth
2.12% 12.00% -109.17% 610.95% 4.72% 11.15% -6.54% 3.51% 5.05% 26.52%
EPS Q/Q Growth
2.26% 12.17% -109.00% 580.43% 8.15% 8.64% -6.56% 3.92% 5.07% 26.59%
Operating Cash Flow Q/Q Growth
-13.05% 26.31% -4.47% -5.07% 11.92% -2.23% 6.45% -7.32% -31.77% 46.18%
Free Cash Flow Firm Q/Q Growth
-118.20% 136.36% -37.81% 281,157.01% -163.80% -36.56% -30.64% -9.03% -323.23% 85.95%
Invested Capital Q/Q Growth
0.74% -12.88% -20.48% -54.60% -8.97% 4.63% 10.86% 10.51% 18.97% 10.07%
Profitability Metrics
- - - - - - - - - -
Gross Margin
74.76% 73.09% 77.73% 78.22% 78.85% 77.66% 74.18% 76.77% 79.25% 81.31%
EBITDA Margin
21.13% 22.95% 19.39% 24.61% 29.12% 34.86% 27.20% 29.18% 23.68% 32.07%
Operating Margin
13.47% 15.37% 10.03% 16.44% 22.29% 24.69% 22.45% 24.97% 18.92% 28.64%
EBIT Margin
13.98% 15.90% 11.54% 17.12% 23.59% 29.46% 21.74% 23.85% 19.21% 28.15%
Profit (Net Income) Margin
12.07% 12.90% -1.02% 15.04% 37.27% 25.24% 19.71% 21.88% 15.36% 23.51%
Tax Burden Percent
86.32% 81.14% -8.86% 87.82% 157.97% 85.67% 90.68% 91.75% 79.95% 83.51%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
13.68% 18.86% 103.75% 14.39% 11.93% 14.33% 9.32% 8.25% 20.05% 16.49%
Return on Invested Capital (ROIC)
19.23% 18.44% -0.58% 31.26% 40.84% 33.67% 31.72% 30.61% 19.05% 29.15%
ROIC Less NNEP Spread (ROIC-NNEP)
16.25% 714.44% -196.04% 18.46% 141.22% 42.67% 30.01% 28.03% 19.53% 28.41%
Return on Net Nonoperating Assets (RNNOA)
-3.16% 0.66% -1.01% -2.63% 81.41% 111.65% 42.80% 32.05% 29.38% 55.11%
Return on Equity (ROE)
16.07% 19.10% -1.59% 28.63% 122.26% 145.32% 74.52% 62.67% 48.43% 84.26%
Cash Return on Invested Capital (CROIC)
-29.40% 27.65% 10.97% 83.19% -25.54% 19.03% 13.78% 16.04% -11.80% -1.55%
Operating Return on Assets (OROA)
7.76% 9.07% 5.50% 8.28% 12.66% 16.83% 12.90% 13.85% 11.55% 17.77%
Return on Assets (ROA)
6.70% 7.36% -0.49% 7.27% 20.00% 14.42% 11.70% 12.71% 9.23% 14.84%
Return on Common Equity (ROCE)
16.05% 19.04% -1.58% 27.17% 111.75% 140.62% 72.74% 61.72% 47.95% 83.69%
Return on Equity Simple (ROE_SIMPLE)
16.53% 19.54% -1.76% 32.88% 319.09% 109.79% 62.16% 58.64% 48.65% 74.62%
Net Operating Profit after Tax (NOPAT)
2,322 2,646 -75 3,026 4,381 5,190 5,765 6,539 5,163 10,773
NOPAT Margin
11.63% 12.47% -0.38% 14.08% 19.63% 21.15% 20.36% 22.91% 15.13% 23.92%
Net Nonoperating Expense Percent (NNEP)
2.98% -696.00% 195.46% 12.81% -100.38% -9.00% 1.71% 2.58% -0.47% 0.75%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 24.21% 14.31% 22.48%
Cost of Revenue to Revenue
25.24% 26.91% 22.27% 21.78% 21.15% 22.34% 25.82% 23.23% 20.75% 18.69%
SG&A Expenses to Revenue
32.73% 30.76% 29.95% 27.80% 27.84% 24.94% 22.71% 22.57% 21.69% 19.08%
R&D to Revenue
26.71% 25.16% 31.08% 32.73% 26.14% 27.49% 27.90% 28.38% 38.43% 31.68%
Operating Expenses to Revenue
61.29% 57.73% 67.70% 61.77% 56.56% 52.97% 51.73% 51.80% 60.32% 52.67%
Earnings before Interest and Taxes (EBIT)
2,790 3,374 2,305 3,680 5,266 7,230 6,156 6,806 6,555 12,680
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4,218 4,871 3,872 5,289 6,499 8,554 7,703 8,329 8,082 14,447
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
5.24 4.87 6.86 11.17 44.29 26.15 27.26 30.52 48.48 49.09
Price to Tangible Book Value (P/TBV)
13.89 12.01 24.92 14.85 0.00 0.00 0.00 0.00 0.00 308.90
Price to Revenue (P/Rev)
3.82 3.21 3.98 5.11 5.17 6.01 8.65 11.39 15.30 15.47
Price to Earnings (P/E)
31.69 24.90 0.00 33.98 13.88 23.82 43.86 52.05 99.65 65.79
Dividend Yield
2.79% 3.18% 2.75% 2.12% 2.09% 1.83% 1.27% 1.09% 0.78% 0.67%
Earnings Yield
3.16% 4.02% 0.00% 2.94% 7.21% 4.20% 2.28% 1.92% 1.00% 1.52%
Enterprise Value to Invested Capital (EV/IC)
5.08 4.92 6.53 15.60 8.85 9.53 12.86 14.67 17.31 16.98
Enterprise Value to Revenue (EV/Rev)
3.82 3.17 3.98 5.20 5.67 6.43 9.00 11.78 15.87 16.07
Enterprise Value to EBITDA (EV/EBITDA)
18.07 13.82 20.55 21.13 19.46 18.43 33.07 40.37 67.01 50.10
Enterprise Value to EBIT (EV/EBIT)
27.32 19.95 34.53 30.37 24.02 21.81 41.39 49.41 82.62 57.08
Enterprise Value to NOPAT (EV/NOPAT)
32.83 25.43 0.00 36.94 28.87 30.38 44.19 51.42 104.89 67.19
Enterprise Value to Operating Cash Flow (EV/OCF)
25.71 13.87 14.17 20.23 26.15 24.26 34.59 44.33 127.72 82.09
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 16.96 56.05 13.88 0.00 53.75 101.75 98.17 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.55 0.73 1.17 0.94 5.67 2.85 1.84 1.51 2.32 2.36
Long-Term Debt to Equity
0.55 0.59 0.85 0.84 5.12 2.85 1.68 1.37 1.69 2.00
Financial Leverage
-0.19 0.00 0.01 -0.14 0.58 2.62 1.43 1.14 1.50 1.94
Leverage Ratio
2.40 2.59 3.25 3.94 6.11 10.08 6.37 4.93 5.25 5.68
Compound Leverage Factor
2.40 2.59 3.25 3.94 6.11 10.08 6.37 4.93 5.25 5.68
Debt to Total Capital
35.35% 42.26% 53.91% 48.56% 85.02% 74.02% 64.84% 60.11% 69.90% 70.22%
Short-Term Debt to Total Capital
0.03% 7.94% 14.64% 5.20% 8.32% 0.04% 5.91% 5.56% 19.13% 10.68%
Long-Term Debt to Total Capital
35.32% 34.31% 39.27% 43.36% 76.70% 73.98% 58.94% 54.56% 50.77% 59.54%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.08% 0.30% 0.30% 5.09% 0.51% 0.82% 0.67% 0.46% 0.25% 0.17%
Common Equity to Total Capital
64.56% 57.44% 45.79% 46.36% 14.47% 25.16% 34.48% 39.42% 29.85% 29.62%
Debt to EBITDA
1.89 2.12 3.52 1.95 2.36 1.94 2.19 1.95 3.12 2.33
Net Debt to EBITDA
-0.03 -0.19 -0.02 0.17 1.68 1.16 1.27 1.34 2.38 1.87
Long-Term Debt to EBITDA
1.89 1.72 2.57 1.74 2.13 1.94 1.99 1.77 2.27 1.97
Debt to NOPAT
3.44 3.89 -181.72 3.40 3.50 3.20 2.93 2.48 4.89 3.12
Net Debt to NOPAT
-0.05 -0.36 0.88 0.29 2.49 1.92 1.69 1.70 3.73 2.51
Long-Term Debt to NOPAT
3.43 3.16 -132.37 3.04 3.15 3.20 2.66 2.25 3.55 2.65
Altman Z-Score
3.78 3.19 2.60 3.36 3.14 3.57 5.04 6.37 6.96 7.90
Noncontrolling Interest Sharing Ratio
0.11% 0.32% 0.58% 5.11% 8.59% 3.24% 2.40% 1.51% 1.00% 0.68%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.53 1.37 1.32 1.73 1.16 1.40 1.23 1.05 0.94 1.15
Quick Ratio
1.04 0.98 0.91 1.11 0.68 0.85 0.80 0.63 0.52 0.59
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3,549 3,968 1,420 8,053 -2,740 2,934 2,504 3,425 -3,198 -572
Operating Cash Flow to CapEx
526.01% 503.42% 521.51% 456.34% 467.80% 468.30% 562.37% 409.09% 122.99% 174.34%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.56 0.57 0.48 0.48 0.54 0.57 0.59 0.58 0.60 0.63
Accounts Receivable Turnover
5.07 4.80 3.98 3.89 3.94 3.94 3.76 3.42 3.43 3.66
Inventory Turnover
1.63 1.63 1.11 1.24 1.50 1.53 1.86 1.62 1.40 1.26
Fixed Asset Turnover
2.49 2.60 2.34 2.56 2.81 2.96 3.21 2.98 2.96 3.00
Accounts Payable Turnover
4.08 4.25 3.22 3.58 3.61 3.64 4.46 3.68 3.13 2.89
Days Sales Outstanding (DSO)
71.99 76.00 91.63 93.73 92.55 92.74 97.03 106.69 106.40 99.72
Days Inventory Outstanding (DIO)
224.11 223.97 329.09 294.56 243.10 238.67 196.31 225.60 259.81 289.67
Days Payable Outstanding (DPO)
89.36 85.89 113.25 102.05 100.98 100.25 81.79 99.13 116.72 126.33
Cash Conversion Cycle (CCC)
206.75 214.08 307.47 286.25 234.66 231.17 211.56 233.17 249.50 263.06
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
15,009 13,688 12,193 7,166 14,287 16,543 19,804 22,918 31,278 42,623
Invested Capital Turnover
1.65 1.48 1.54 2.22 2.08 1.59 1.56 1.34 1.26 1.22
Increase / (Decrease) in Invested Capital
5,871 -1,322 -1,495 -5,027 7,121 2,256 3,261 3,114 8,361 11,345
Enterprise Value (EV)
76,226 67,295 79,588 111,783 126,461 157,672 254,751 336,279 541,565 723,817
Market Capitalization
76,327 68,163 79,578 109,818 115,453 147,541 244,812 325,028 522,228 696,733
Book Value per Share
$13.15 $12.69 $10.53 $9.28 $2.72 $5.90 $9.39 $11.21 $11.35 $14.95
Tangible Book Value per Share
$4.96 $5.14 $2.90 $6.98 ($8.01) ($5.83) ($2.72) ($0.66) ($1.13) $2.38
Total Capital
22,569 24,386 25,315 21,208 18,016 22,421 26,040 27,014 36,089 47,916
Total Debt
7,979 10,305 13,647 10,299 15,317 16,595 16,885 16,239 25,225 33,644
Total Long-Term Debt
7,972 8,368 9,941 9,196 13,818 16,587 15,346 14,738 18,321 28,527
Net Debt
-120 -941 -66 884 10,916 9,947 9,764 11,125 19,245 27,005
Capital Expenditures (CapEx)
564 964 1,077 1,211 1,034 1,388 1,310 1,854 3,448 5,058
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-102 14 339 2,355 995 1,308 1,029 186 2,411 6,057
Debt-free Net Working Capital (DFNWC)
4,350 6,052 8,373 9,764 3,434 4,989 4,938 2,397 5,338 9,480
Net Working Capital (NWC)
4,344 4,115 4,666 8,662 1,934 4,981 3,400 896 -1,566 4,363
Net Nonoperating Expense (NNE)
-87 -92 129 -206 -3,937 -1,004 183 294 -77 183
Net Nonoperating Obligations (NNO)
419 -393 525 -3,743 11,588 10,718 10,649 12,142 20,415 28,351
Total Depreciation and Amortization (D&A)
1,428 1,497 1,567 1,609 1,233 1,324 1,548 1,523 1,527 1,767
Debt-free, Cash-free Net Working Capital to Revenue
-0.51% 0.06% 1.70% 10.96% 4.46% 5.33% 3.64% 0.65% 7.06% 13.45%
Debt-free Net Working Capital to Revenue
21.80% 28.52% 41.92% 45.43% 15.38% 20.33% 17.44% 8.40% 15.64% 21.05%
Net Working Capital to Revenue
21.76% 19.39% 23.36% 40.30% 8.67% 20.30% 12.01% 3.14% -4.59% 9.69%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $8.93 $6.82 $6.15 $6.93 $5.82 $11.76
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 0.00 931.06M 907.63M 906.96M 901.74M 900.18M 900.61M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $8.89 $6.79 $6.12 $6.90 $5.80 $11.71
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 0.00 935.68M 912.51M 911.68M 904.62M 903.28M 904.06M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 0.00 956.38M 958.43M 952.35M 950.30M 950.16M 948.17M
Normalized Net Operating Profit after Tax (NOPAT)
2,639 2,956 2,334 3,254 4,888 5,302 6,051 6,764 5,217 11,491
Normalized NOPAT Margin
13.22% 13.93% 11.69% 15.14% 21.90% 21.61% 21.37% 23.70% 15.29% 25.51%
Pre Tax Income Margin
13.98% 15.90% 11.54% 17.12% 23.59% 29.46% 21.74% 23.85% 19.21% 28.15%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
88.33% 78.85% -1,074.03% 71.53% 28.97% 43.38% 55.30% 56.62% 77.65% 44.20%
Augmented Payout Ratio
119.45% 100.77% -1,220.92% 199.95% 81.86% 51.46% 77.70% 80.64% 91.96% 67.80%

Quarterly Metrics and Ratios for Eli Lilly and Company

This table displays calculated financial ratios and metrics derived from Eli Lilly and Company's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
2.49% -8.73% -10.88% 28.12% 36.84% 28.10% 25.98% 35.98% 20.43% 44.68% 45.17%
EBITDA Growth
18.48% 8.13% -23.99% 70.52% -56.53% 17.20% 55.22% 60.13% 145.19% 90.70% 33.45%
EBIT Growth
25.71% 13.94% -25.51% 91.48% -72.71% 19.67% 65.79% 68.38% 271.82% 100.84% 36.28%
NOPAT Growth
-7.29% -5.63% -41.04% 69.82% -103.89% 22.78% 68.93% 74.65% 1,640.76% 116.22% 32.95%
Net Income Growth
30.77% 12.26% -29.32% 85.11% -103.95% 13.01% 66.77% 68.27% 1,790.42% 101.39% 23.02%
EPS Growth
31.97% 13.83% -29.05% 85.71% -103.73% 13.08% 66.44% 68.21% 1,883.33% 101.65% 23.39%
Operating Cash Flow Growth
35.89% -26.48% -31.41% -46.60% -1.23% -118.76% -32.62% 132.03% 69.53% 893.14% 42.85%
Free Cash Flow Firm Growth
-251.68% 3.13% -24.01% 6.70% -325.46% -343.13% -321.33% -244.64% -104.87% -8.95% -54.65%
Invested Capital Growth
16.09% 15.72% 14.91% 20.83% 26.78% 36.48% 40.73% 47.40% 47.29% 36.27% 43.32%
Revenue Q/Q Growth
6.99% 5.19% -4.68% 19.43% 14.27% -1.53% -6.26% 28.91% 1.21% 18.30% -5.94%
EBITDA Q/Q Growth
33.94% 28.16% -23.44% 29.77% -65.86% 245.56% 1.39% 33.88% -47.73% 168.76% -29.05%
EBIT Q/Q Growth
43.51% 33.91% -27.03% 36.56% -79.55% 487.27% 1.09% 38.69% -54.84% 217.22% -31.41%
NOPAT Q/Q Growth
47.14% 9.18% -22.62% 36.60% -103.37% 3,543.80% 6.47% 41.23% -70.25% 383.27% -34.53%
Net Income Q/Q Growth
52.41% 33.48% -30.59% 31.10% -103.26% 3,914.81% 2.43% 32.28% -67.30% 354.48% -37.43%
EPS Q/Q Growth
53.33% 32.92% -30.37% 30.87% -103.08% 4,133.33% 2.48% 32.26% -67.38% 356.07% -37.30%
Operating Cash Flow Q/Q Growth
87.33% -24.99% 4.08% -63.49% 246.49% -114.25% 473.84% 25.75% 153.16% -33.35% -32.67%
Free Cash Flow Firm Q/Q Growth
52.40% -7.36% -24.97% -46.08% -117.08% -11.82% -18.82% -19.49% -29.04% 40.53% -68.66%
Invested Capital Q/Q Growth
-1.40% 10.51% 3.67% 6.96% 3.46% 18.97% 6.90% 12.03% 3.38% 10.07% 12.43%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
77.25% 78.80% 76.63% 78.26% 80.42% 80.88% 80.91% 80.80% 81.02% 82.24% 82.53%
EBITDA Margin
27.78% 33.85% 27.18% 29.54% 8.82% 30.97% 33.49% 34.78% 17.97% 40.82% 30.79%
Operating Margin
24.15% 25.15% 21.47% 25.57% 4.74% 25.53% 28.62% 32.87% 13.34% 38.05% 29.03%
EBIT Margin
22.55% 28.71% 21.98% 25.13% 4.50% 26.82% 28.92% 31.12% 13.89% 37.23% 27.15%
Profit (Net Income) Margin
20.91% 26.54% 19.32% 21.21% -0.60% 23.41% 25.58% 26.25% 8.48% 32.59% 21.68%
Tax Burden Percent
92.73% 92.43% 87.92% 84.41% -13.44% 87.28% 88.44% 84.36% 61.09% 87.52% 79.84%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
7.27% 7.57% 12.08% 15.59% 113.44% 12.72% 11.56% 15.64% 38.91% 12.48% 20.16%
Return on Invested Capital (ROIC)
33.93% 31.06% 23.52% 27.44% -0.87% 28.06% 31.80% 34.33% 10.25% 40.59% 27.92%
ROIC Less NNEP Spread (ROIC-NNEP)
32.92% 33.17% 23.79% 27.20% -0.84% 28.71% 31.94% 33.45% 10.44% 40.20% 27.20%
Return on Net Nonoperating Assets (RNNOA)
37.21% 37.93% 27.13% 36.58% -1.01% 43.19% 43.58% 51.40% 16.04% 77.98% 49.78%
Return on Equity (ROE)
71.14% 68.99% 50.66% 64.01% -1.87% 71.25% 75.37% 85.73% 26.29% 118.57% 77.70%
Cash Return on Invested Capital (CROIC)
19.51% 16.04% 11.45% 8.55% -3.21% -11.80% -12.62% -14.77% -12.53% -1.55% -7.33%
Operating Return on Assets (OROA)
13.79% 16.67% 12.16% 14.56% 2.74% 16.13% 17.75% 19.12% 8.50% 23.50% 17.36%
Return on Assets (ROA)
12.79% 15.41% 10.69% 12.29% -0.37% 14.08% 15.70% 16.13% 5.19% 20.57% 13.86%
Return on Common Equity (ROCE)
69.99% 67.95% 50.08% 63.37% -1.86% 70.54% 74.78% 85.18% 26.12% 117.77% 77.25%
Return on Equity Simple (ROE_SIMPLE)
59.91% 0.00% 50.82% 58.73% 44.46% 0.00% 47.91% 54.14% 58.78% 0.00% 70.45%
Net Operating Profit after Tax (NOPAT)
1,555 1,697 1,314 1,794 -61 2,084 2,219 3,134 932 4,506 2,950
NOPAT Margin
22.40% 23.25% 18.87% 21.59% -0.64% 22.28% 25.31% 27.72% 8.15% 33.30% 23.18%
Net Nonoperating Expense Percent (NNEP)
1.01% -2.11% -0.27% 0.23% -0.02% -0.65% -0.15% 0.88% -0.19% 0.40% 0.73%
Return On Investment Capital (ROIC_SIMPLE)
- 6.28% - - - 5.77% - - - 9.40% 5.43%
Cost of Revenue to Revenue
22.75% 21.20% 23.37% 21.74% 19.58% 19.12% 19.09% 19.20% 18.98% 17.76% 17.47%
SG&A Expenses to Revenue
23.25% 22.50% 25.13% 23.16% 18.99% 20.58% 22.27% 18.73% 18.36% 17.92% 19.40%
R&D to Revenue
26.87% 30.62% 30.03% 29.52% 56.68% 34.06% 30.03% 25.35% 48.61% 23.73% 33.82%
Operating Expenses to Revenue
53.10% 53.65% 55.16% 52.68% 75.68% 55.36% 52.30% 47.93% 67.68% 44.19% 53.50%
Earnings before Interest and Taxes (EBIT)
1,566 2,096 1,530 2,089 427 2,509 2,536 3,517 1,588 5,039 3,456
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,928 2,471 1,892 2,455 838 2,897 2,937 3,932 2,055 5,524 3,919
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
28.52 30.52 27.41 37.93 42.79 48.48 54.71 60.28 56.30 49.09 47.18
Price to Tangible Book Value (P/TBV)
0.00 0.00 10,155.10 5,155.08 1,358.09 0.00 631.25 706.14 414.50 308.90 186.79
Price to Revenue (P/Rev)
9.82 11.39 11.08 14.22 14.97 15.30 19.51 21.00 19.62 15.47 15.18
Price to Earnings (P/E)
47.60 52.05 53.93 64.58 96.24 99.65 114.19 111.34 95.79 65.79 66.97
Dividend Yield
1.19% 1.09% 1.20% 0.91% 0.82% 0.78% 0.60% 0.54% 0.57% 0.67% 0.65%
Earnings Yield
2.10% 1.92% 1.85% 1.55% 1.04% 1.00% 0.88% 0.90% 1.04% 1.52% 1.49%
Enterprise Value to Invested Capital (EV/IC)
14.36 14.67 13.44 17.04 18.83 17.31 21.58 22.43 21.34 16.98 16.19
Enterprise Value to Revenue (EV/Rev)
10.19 11.78 11.53 14.67 15.44 15.87 20.08 21.59 20.22 16.07 15.84
Enterprise Value to EBITDA (EV/EBITDA)
36.58 40.37 41.29 49.50 64.67 67.01 79.06 79.24 69.90 50.10 50.29
Enterprise Value to EBIT (EV/EBIT)
45.47 49.41 50.82 59.47 80.62 82.62 95.43 93.47 81.40 57.08 57.05
Enterprise Value to NOPAT (EV/NOPAT)
44.86 51.42 56.73 68.02 103.22 104.89 118.94 113.52 98.84 67.19 67.46
Enterprise Value to Operating Cash Flow (EV/OCF)
36.39 44.33 47.00 69.36 79.67 127.72 196.32 186.31 136.97 82.09 83.28
Enterprise Value to Free Cash Flow (EV/FCFF)
79.10 98.17 125.50 218.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.56 1.51 1.67 1.69 1.78 2.32 2.03 2.12 2.17 2.36 2.43
Long-Term Debt to Equity
1.39 1.37 1.67 1.63 1.59 1.69 1.90 1.74 2.03 2.00 2.18
Financial Leverage
1.13 1.14 1.14 1.34 1.19 1.50 1.36 1.54 1.54 1.94 1.83
Leverage Ratio
5.28 4.93 4.82 5.14 4.91 5.25 4.84 5.11 5.21 5.68 5.33
Compound Leverage Factor
5.28 4.93 4.82 5.14 4.91 5.25 4.84 5.11 5.21 5.68 5.33
Debt to Total Capital
60.98% 60.11% 62.57% 62.80% 64.08% 69.90% 67.02% 67.94% 68.48% 70.22% 70.85%
Short-Term Debt to Total Capital
6.70% 5.56% 0.01% 2.21% 7.13% 19.13% 4.22% 12.14% 4.56% 10.68% 7.39%
Long-Term Debt to Total Capital
54.29% 54.56% 62.56% 60.59% 56.94% 50.77% 62.80% 55.80% 63.92% 59.54% 63.46%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.37% 0.46% 0.35% 0.29% 0.28% 0.25% 0.22% 0.17% 0.18% 0.17% 0.15%
Common Equity to Total Capital
38.65% 39.42% 37.08% 36.92% 35.65% 29.85% 32.76% 31.89% 31.34% 29.62% 29.00%
Debt to EBITDA
1.95 1.95 2.44 2.15 2.63 3.12 2.87 2.72 2.63 2.33 2.50
Net Debt to EBITDA
1.30 1.34 1.61 1.51 1.96 2.38 2.25 2.14 2.06 1.87 2.08
Long-Term Debt to EBITDA
1.74 1.77 2.44 2.08 2.34 2.27 2.69 2.24 2.46 1.97 2.24
Debt to NOPAT
2.39 2.48 3.36 2.96 4.20 4.89 4.32 3.90 3.72 3.12 3.35
Net Debt to NOPAT
1.59 1.70 2.21 2.08 3.12 3.73 3.39 3.06 2.92 2.51 2.79
Long-Term Debt to NOPAT
2.13 2.25 3.36 2.85 3.74 3.55 4.05 3.21 3.47 2.65 3.00
Altman Z-Score
5.69 6.06 5.40 6.75 7.03 6.75 9.33 9.43 8.82 7.58 7.13
Noncontrolling Interest Sharing Ratio
1.62% 1.51% 1.14% 1.01% 0.85% 1.00% 0.78% 0.64% 0.65% 0.68% 0.58%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.13 1.05 1.30 1.13 1.05 0.94 1.35 1.11 1.27 1.15 1.37
Quick Ratio
0.71 0.63 0.79 0.63 0.58 0.52 0.68 0.61 0.63 0.59 0.57
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,319 -1,416 -1,770 -2,586 -5,613 -6,277 -7,458 -8,911 -11,499 -6,839 -11,534
Operating Cash Flow to CapEx
359.15% 332.08% 258.88% 85.60% 225.65% -29.13% 118.22% 119.71% 274.81% 165.36% 110.34%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.61 0.58 0.55 0.58 0.61 0.60 0.61 0.61 0.61 0.63 0.64
Accounts Receivable Turnover
3.81 3.42 3.29 3.50 3.43 3.43 3.78 3.50 3.65 3.66 4.08
Inventory Turnover
1.84 1.62 1.47 1.51 1.57 1.40 1.34 1.33 1.26 1.26 1.16
Fixed Asset Turnover
3.21 2.98 2.82 2.89 3.03 2.96 2.97 2.98 2.92 3.00 3.05
Accounts Payable Turnover
4.39 3.68 3.59 3.17 3.32 3.13 3.18 2.78 2.93 2.89 3.03
Days Sales Outstanding (DSO)
95.81 106.69 110.90 104.15 106.34 106.40 96.68 104.33 100.11 99.72 89.44
Days Inventory Outstanding (DIO)
198.02 225.60 249.00 241.93 232.92 259.81 272.55 274.79 289.13 289.67 313.62
Days Payable Outstanding (DPO)
83.17 99.13 101.79 114.97 109.84 116.72 114.93 131.52 124.47 126.33 120.37
Cash Conversion Cycle (CCC)
210.66 233.17 258.12 231.11 229.41 249.50 254.30 247.59 264.77 263.06 282.69
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
20,738 22,918 23,759 25,411 26,290 31,278 33,436 37,456 38,722 42,623 47,919
Invested Capital Turnover
1.51 1.34 1.25 1.27 1.36 1.26 1.26 1.24 1.26 1.22 1.20
Increase / (Decrease) in Invested Capital
2,874 3,114 3,084 4,380 5,553 8,361 9,677 12,045 12,432 11,345 14,484
Enterprise Value (EV)
297,855 336,279 319,252 432,955 495,154 541,565 721,568 840,226 826,258 723,817 775,969
Market Capitalization
287,188 325,028 306,684 419,623 480,084 522,228 700,944 817,502 801,776 696,733 743,815
Book Value per Share
$10.60 $11.21 $11.78 $11.66 $11.82 $11.35 $14.22 $14.27 $14.98 $14.95 $16.63
Tangible Book Value per Share
($1.00) ($0.66) $0.03 $0.09 $0.37 ($1.13) $1.23 $1.22 $2.04 $2.38 $4.20
Total Capital
26,054 27,014 30,179 29,969 31,476 36,089 39,109 42,528 45,440 47,916 54,363
Total Debt
15,888 16,239 18,884 18,820 20,168 25,225 26,211 28,892 31,120 33,644 38,516
Total Long-Term Debt
14,144 14,738 18,881 18,158 17,924 18,321 24,560 23,730 29,045 28,527 34,500
Net Debt
10,572 11,125 12,464 13,246 14,983 19,245 20,538 22,650 24,401 27,005 32,073
Capital Expenditures (CapEx)
617 501 669 738 970 1,071 986 1,225 1,351 1,496 1,510
Debt-free, Cash-free Net Working Capital (DFCFNWC)
990 186 1,135 249 760 2,411 5,656 4,881 5,297 6,057 11,989
Debt-free Net Working Capital (DFNWC)
3,732 2,397 4,805 3,078 3,254 5,338 8,242 8,245 8,815 9,480 15,210
Net Working Capital (NWC)
1,987 896 4,801 2,417 1,009 -1,566 6,591 3,083 6,741 4,363 11,193
Net Nonoperating Expense (NNE)
103 -240 -31 31 -3.12 -106 -24 167 -38 96 191
Net Nonoperating Obligations (NNO)
10,572 12,142 12,464 14,262 14,983 20,415 20,538 23,821 24,401 28,351 32,073
Total Depreciation and Amortization (D&A)
363 375 362 366 411 388 401 414 467 485 463
Debt-free, Cash-free Net Working Capital to Revenue
3.38% 0.65% 4.10% 0.84% 2.37% 7.06% 15.74% 12.54% 12.96% 13.45% 24.47%
Debt-free Net Working Capital to Revenue
12.76% 8.40% 17.35% 10.43% 10.14% 15.64% 22.94% 21.18% 21.57% 21.05% 31.04%
Net Working Capital to Revenue
6.80% 3.14% 17.34% 8.19% 3.15% -4.59% 18.34% 7.92% 16.50% 9.69% 22.84%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.61 $2.15 $1.49 $1.96 ($0.06) $2.43 $2.49 $3.29 $1.08 $4.90 $3.07
Adjusted Weighted Average Basic Shares Outstanding
900.70M 901.74M 901M 899.70M 899.80M 900.18M 900.80M 900.90M 901M 900.61M 898.70M
Adjusted Diluted Earnings per Share
$1.61 $2.14 $1.49 $1.95 ($0.06) $2.42 $2.48 $3.28 $1.07 $4.88 $3.06
Adjusted Weighted Average Diluted Shares Outstanding
903.80M 904.62M 903.30M 902.70M 899.80M 903.28M 903.80M 904.20M 905M 904.06M 900.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
950.18M 950.30M 949.27M 949.30M 949.31M 950.16M 950.41M 950.43M 949.32M 948.17M 947.74M
Normalized Net Operating Profit after Tax (NOPAT)
1,746 1,697 1,314 1,794 315 2,084 2,219 3,501 982 4,506 2,978
Normalized NOPAT Margin
25.15% 23.25% 18.87% 21.59% 3.32% 22.28% 25.31% 30.97% 8.59% 33.30% 23.40%
Pre Tax Income Margin
22.55% 28.71% 21.98% 25.13% 4.50% 26.82% 28.92% 31.12% 13.89% 37.23% 27.15%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
56.76% 56.62% 64.49% 58.51% 78.90% 77.65% 68.77% 59.60% 54.12% 44.20% 43.74%
Augmented Payout Ratio
94.06% 80.64% 77.68% 70.05% 93.93% 91.96% 68.77% 59.60% 59.45% 67.80% 77.05%

Frequently Asked Questions About Eli Lilly and Company's Financials

When does Eli Lilly and Company's fiscal year end?

According to the most recent income statement we have on file, Eli Lilly and Company's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Eli Lilly and Company's net income changed over the last 9 years?

Eli Lilly and Company's net income appears to be on an upward trend, with a most recent value of $10.59 billion in 2024, rising from $2.41 billion in 2015. The previous period was $5.24 billion in 2023. See Eli Lilly and Company's forecast for analyst expectations on what’s next for the company.

What is Eli Lilly and Company's operating income?
Eli Lilly and Company's total operating income in 2024 was $12.90 billion, based on the following breakdown:
  • Total Gross Profit: $36.62 billion
  • Total Operating Expenses: $23.73 billion
How has Eli Lilly and Company revenue changed over the last 9 years?

Over the last 9 years, Eli Lilly and Company's total revenue changed from $19.96 billion in 2015 to $45.04 billion in 2024, a change of 125.7%.

How much debt does Eli Lilly and Company have?

Eli Lilly and Company's total liabilities were at $64.44 billion at the end of 2024, a 21.3% increase from 2023, and a 207.2% increase since 2015.

How much cash does Eli Lilly and Company have?

In the past 9 years, Eli Lilly and Company's cash and equivalents has ranged from $2.07 billion in 2022 to $7.32 billion in 2018, and is currently $3.27 billion as of their latest financial filing in 2024.

How has Eli Lilly and Company's book value per share changed over the last 9 years?

Over the last 9 years, Eli Lilly and Company's book value per share changed from 13.15 in 2015 to 14.95 in 2024, a change of 13.7%.



This page (NYSE:LLY) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners